Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
일본 히로시마에서 Sanger 시퀀싱 전략을 사용한 SARS-COV-2 변이체의 질량 스크리닝
Article
[키워드] (Alpha)
Alpha
amplification
amplified
amplified product
amplified products
applied
assigned
B.1.1.529
B.1.1.7
B.1.351
B.1.617.1
B.1.617.2
Cluster
confirmed case
country
COVID-19
develop
E484K
effective
Effectiveness
Epidemiology
feasible
genome sequence
Genome sequences
HCoV
Hiroshima
house
identify
indicate
isolates
Japan
less
mass
Mass screening
mutant
Mutation
next generation sequencing
NGS
notable
number of sample
number of samples
P.1
pandemic
PCR-based techniques
positive
Prevention and control
primer
primer set
primer sets
Primers
protocol
Randomly
readiness
reliability
repeated
reported
RT-PCR
Sanger sequencing
SARS-CoV-2
SARS-CoV-2 variant
SARS-CoV-2 variants
screened
Screening
screening strategy
selected
single mutation
Strategy
variant
[DOI] 10.1038/s41598-022-04952-2 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-022-04952-2 PMC 바로가기 [Article Type] Article